---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-062937"
form_type: "8-K"
ticker: "DSGN"
cik: "0001807120"
company_name: "Design Therapeutics, Inc."
filed_at: "2023-11-13T23:59:59+00:00"
generated_at: "2026-06-08T05:21:23.015420+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Design Therapeutics reports Q3 net loss of $15.8M, extends cash runway to 5 years, appoints Pratik Shah as CEO

## Summary
- Net loss of $15.8M for Q3 2023; R&D expenses $13.3M, G&A expenses $5.6M.
- Cash and securities of $290.9M as of Sep 30, 2023, expected to fund operations through at least 2028.
- Strategic realignment initiated to prioritize long-term growth, focus capital, and implement cost savings.
- Pratik Shah appointed as Chief Executive Officer, leading company turnaround and portfolio review.
- Comprehensive corporate and pipeline update planned for early 2024.

## SEC filing metadata
- accession: 0000950170-23-062937
- form_type: 8-K
- ticker: DSGN
- cik: 0001807120
- company_name: Design Therapeutics, Inc.
- filed_at: 2023-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1807120/000095017023062937/0000950170-23-062937-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1807120/000095017023062937/dsgn-20231113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-062937
- JSON: https://secwatch.observer/filing/0000950170-23-062937.json
- Plain text: https://secwatch.observer/filing/0000950170-23-062937.txt

## Key facts
- Earnings Releases
  Design Therapeutics, Inc. reported third quarter 2023 results: net income Net loss was $15.8 million for the quarter ended September 30, 2023.. Guidance reaffirmed.
  - Period: third quarter 2023
  - Net income: Net loss was $15.8 million for the quarter ended September 30, 2023.
  - Guidance: reaffirmed
  - Result: reported results
  source text: Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today reported third quarter 2023 financial results.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1807120/000095017023062937/0000950170-23-062937-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.